• 1. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 2. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

Research Brief on (±)-2-Bromobutyric-2,3,3,4,4,4-d6 Acid (CAS: 1219799-08-2): Recent Advances and Applications

The compound (±)-2-Bromobutyric-2,3,3,4,4,4-d6 Acid (CAS: 1219799-08-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This deuterated analog of 2-bromobutyric acid is increasingly utilized as a stable isotope-labeled intermediate in the synthesis of pharmaceuticals, metabolic studies, and proteomics research. Its unique isotopic labeling pattern (d6) enhances its utility in mass spectrometry-based analyses, providing improved sensitivity and accuracy in tracing metabolic pathways and drug metabolism studies.

Recent studies have highlighted the role of (±)-2-Bromobutyric-2,3,3,4,4,4-d6 Acid in the development of novel anticancer agents. Researchers have employed this compound as a key building block in the synthesis of bromodomain inhibitors, which target epigenetic regulators involved in cancer progression. The deuterium labeling facilitates pharmacokinetic studies by reducing metabolic degradation, thereby improving the compound's half-life and bioavailability. This property is particularly valuable in preclinical drug development, where understanding the metabolic fate of potential therapeutics is critical.

In addition to its applications in oncology, (±)-2-Bromobutyric-2,3,3,4,4,4-d6 Acid has been instrumental in neurodegenerative disease research. A 2023 study demonstrated its use in synthesizing deuterated analogs of neuroprotective agents, enabling researchers to track drug distribution and metabolism in the brain with unprecedented precision. The compound's stability under physiological conditions makes it an ideal candidate for in vivo studies, providing insights into blood-brain barrier penetration and tissue-specific drug accumulation.

The synthetic methodology for (±)-2-Bromobutyric-2,3,3,4,4,4-d6 Acid has also seen significant advancements. Recent publications describe improved catalytic systems for its preparation, achieving higher yields and enantiomeric purity. These developments are crucial for scaling up production to meet the growing demand from pharmaceutical companies engaged in deuterated drug development. Furthermore, novel purification techniques have been reported that enhance the compound's stability during storage, addressing previous challenges related to its shelf life.

Looking forward, the unique properties of (±)-2-Bromobutyric-2,3,3,4,4,4-d6 Acid position it as a versatile tool in drug discovery and development. Its applications extend beyond small molecule therapeutics to include peptide-based drugs and antibody-drug conjugates, where deuterium labeling can provide critical insights into stability and biodistribution. As the pharmaceutical industry continues to embrace deuterium incorporation as a strategy to optimize drug properties, the importance of this compound and related analogs is expected to grow substantially in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)